

Introduction to Medical Office Real Estate

Pantheon invests in essential real estate sectors that benefit from secular demand drivers and offer strong risk-adjusted returns regardless of economic environment. This paper is designed to introduce the medical office real estate (“MOB”) sector broadly, explain the inherent dynamics that differentiate it from other property types and highlight elements of Pantheon’s strategy to invest in the sector.



Highlights:


- ▶ MOBs are essential to the tenants and communities they serve and remain undersupplied to meet the needs of a changing delivery model that prioritizes value- and convenience-based care in outpatient settings.
- ▶ Pantheon believes that small-format (<25,000 sq. ft.) MOBs, often triple-net leased to one or two tenants providing specialized treatment services, either in “retail” locations (i.e., more accessible to the patients) or in conjunction with a nearby larger hospital’s outpatient services, have the potential to offer an attractive yield spread to where larger, multi-tenant MOB assets are currently trading.
- ▶ Additionally, smaller-format MOBs remain fragmented and may often be overlooked by public and private institutional investors; Pantheon believes that that market segment offers the opportunity to secure accretive financing, generate strong/predictable current yield, and benefit from portfolio exit optionality.
- ▶ Pantheon believes that as a result of secular tailwinds supporting demand for outpatient healthcare and the sector’s defensive nature (lowest peak-to-trough declines in occupancy and NOI growth of all major real estate sectors during both the GFC and COVID pandemic), the medical office sector will experience continued institutional capital inflows and compression in cap rates to levels consistent with other established core property sectors.

1. Overview of Medical Office Real Estate


Medical office buildings play a vital role in the U.S. healthcare system and represent a large, diverse investable universe

- ▶ Medical office buildings are leased to tenants providing outpatient healthcare services; located either on a hospital campus or in conveniently accessible retail / commercial locations ('off-campus')
- ▶ Tenants include hospital / health systems, physician-owned practices, and other publicly- and privately-owned specialty care providers.
- ▶ Properties can be leased to a single tenant providing one or more different kinds of care or to multiple tenants providing different kinds of care in the same building.
- ▶ The U.S. healthcare delivery model continues to shift toward a value-based care approach, which aims to control system-wide costs by incentivizing care that can prevent / delay the onset of serious conditions requiring more costly hospitalization (i.e., regular visits to GP and specialists); the shifting compensation model is contributing to strong growth in outpatient care.

Medical Real Estate By Type (by SF) ¹



MOB Tenant Uses (REIT Portfolios) ²




	Outpatient	Inpatient
Tenant Uses	Primary care, specialty clinics, outpatient surgery	Acute care hospitals, extended stay / rehabilitation clinics (i.e., occupational therapy, behavioral health)
Tenant Types	For-profit and not-for-profit health systems, physicians' groups, specialty providers (i.e., dialysis, blood plasma, cancer treatment)	For-profit and not-for-profit health systems, rehab operators, govt.
Tenant Credit Profile	Diverse, with most institutional investors focused on investment grade or large PE-backed tenants	Largely investment grade or govt., some non-rated health systems and operators
Typical Lease Term in Years (Initial / Renewal)	Single-tenant: 10 / 5-7 (NNN or NN) Multi-tenant: 5-10 / 5-7 (gross, NN, NNN)	Largely single-tenant w/ long-term leases 15+ years
Landlord Capex	Single-tenant: low due to NNN / less turnover Multi-tenant: higher due to shorter leases, common areas	Low due to long-term / NNN leases, no common areas





¹Source: JLL; Revista – as of Q1'2023. ²Source: Evercore - 2022.

1. Overview of Medical Office Real Estate (continued)

MOBs are predominantly leased to tenants providing higher-acuity, specialty care, requiring tenants to invest significant upfront capital in their spaces for infrastructure upgrades, patient areas, and installation of equipment; tenant upfront expenditure acts as a disincentive for tenant relocation and contributes to high retention rates vs. other commercial property types.

- ▶ Pantheon has recently been able to acquire well-performing, tenanted properties at a discount to their replacement cost.¹
- ▶ Well-performing tenants often have little incentive to move to newly constructed properties that require higher rents to make a return on an inflated costs basis.




Estimated Buildout Costs ³		
	Dialysis Clinics	<p>\$275/sf + land and base building</p> <ul style="list-style-type: none"> Upgraded water / sewer lines, mechanical systems and electrical Installation of specialized water filtration system and dialysis equipment
	Physician's Offices	<p>\$355/sf + land and base building</p> <ul style="list-style-type: none"> Subdivided with examination rooms, waiting areas and office space Upgraded IT systems, especially given growth of telehealth and new in-office treatments
	Moderate Intensity Uses	<p>\$455/sf + land and base building</p> <ul style="list-style-type: none"> Baseline costs of a physician's office + features to support a specialty focus (i.e., high-density floorplates for heavy equipment) Examples: wound care clinics (hyperbaric chamber), imaging centers (radiology rooms)
	High Intensity Uses	<p>\$655/sf + land and base building</p> <ul style="list-style-type: none"> Baseline costs of a physician's office, plus features to support a specialty focus (high ceilings for equipment, backup generators, enhanced HVAC) Examples: surgery centers and cancer treatment facilities

¹There is no guarantee that these trends will continue. ²Source: JLL, Pantheon. ³Source: JLL; Revista – as of Q1'2023.

1. Overview of Medical Office Real Estate (continued)

Despite strong inflows from institutional investors over the last decade, MOB ownership remains fragmented, with end-users owning over 60% of all MOB¹

- ▶ As hospitals / health systems face higher operating costs and credit markets tighten, Pantheon expects a growing number of sale-leaseback transactions in coming years from operators seeking liquidity through the monetization of underlying real estate portfolios.²
 - ▶ Sale-leaseback transactions can provide long-term leases backed by strong credit, often requiring minimal landlord capital expenditures.
- ▶ Of the 37% of MOB^s owned by investors, public REITs and private investors account for 35% and 65% ownership, respectively.¹
 - ▶ The top-10 private investors account for only 17% of investor-owned MOB^s, with smaller and non-institutional private investors accounting for 48% of all investor-owned MOB^s, providing a significant runway for further consolidation.^{1,3}



MOB REIT Ownership Snapshot⁴

- ▶ The top-5 REIT owners of MOB include diversified healthcare and ‘pure-play’ MOB REITs – these REITs tend to target larger, multi-tenant MOB^s given their large market capitalizations and requirement for investment scale.⁵
- ▶ GMRE and CHCT are examples of smaller healthcare REITs that target small-format MOB^s, evidencing institutional demand for Pantheon’s target property type.⁵

	% of Portfolio - MOB	MOB Property Count	MOB Ownership (sq. ft.)	Avg. Property Size (sq. ft.)	Occupancy	WALT	Tenancy Profile	% On / Off Campus	Q1'23 - S/S NOI Growth
Top-5 MOB REIT Owners - Avg.	58%	395	115.0m	58k	92%	6.4 yrs	70% health systems	67% / 33%	2.4%
Global Medical REIT (NYSE: GMRE)	75%	165	3.7m	22k	97%	6.0 yrs	<25% IG credit	n/a	2.1%
Community Healthcare Trust (NYSE: CHCT)	69%	149	2.7m	18k	n/a	n/a	n/a	n/a	n/a
Pantheon Target Portfolio	100%	-	-	<25k	95-100%	6.0+ yrs	90%+ IG credit	~30% / 70%	2.0%+

¹Source: JLL, Revista, Real Capital Analytics – as of Q1'2023. ²There is no guarantee that these trends will continue. ³Pantheon opinion ⁴Excludes MOB^s owned by hospitals / health systems and govt. / other non-private owners. ⁵Source: Public information as of Q1'2023. Top-5 REIT MOB owners include HR, PEAK, WELL, VTR, DOC.

2. Small-Format MOB

Pantheon believes small-format MOB represent an attractive market segment, with an opportunity to acquire properties leased to specialty providers with strong credit, but at higher cap rates vs. larger / multi-tenant properties, and achieve a portfolio premium at exit.¹

- ▶ Small-format MOB characterized by properties <25,000 sq. ft., primarily single-tenant (sometimes 2-3 tenants); usually NNN-leased to health systems and specialty care providers (i.e., dialysis, imaging, cardiology, oncology, etc.)
- ▶ Small-format MOB market segment **benefits from the same underlying trends** and investment attributes as larger / multi-tenant MOB, including:
 - ▶ High concentration of tenants providing higher acuity specialty care
 - ▶ Large universe of properties leased by credit-backed tenants
 - ▶ Wide availability of financing for properties leased to strong tenants
- ▶ Small-format MOB segment presents **distinct advantages/opportunities not offered in the larger MOB market segment**¹:
 - ▶ Typical transactions involving small-format MOB are too small for REITs / institutional buyers; as a result, **they can be acquired at higher going-in cap rates** vs. larger properties, despite similar fundamentals and risk profiles.
 - ▶ Highly fragmented ownership and prevalence of non-institutional sellers (local developers, HNW individuals, physicians) provide an opportunity to **create value through off-market or limited-marketed acquisitions**
 - ▶ Opportunity to identify shorter weighted-average lease term (“WALT”) properties at **above-market cap rates**; leverage operational expertise and industry relationships to extend / renew tenant leases and achieve **WALT-premium (cap rate compression) at sale**.
 - ▶ **NNN leases** more common vs. multi-tenant, **resulting in minimal leakage from rent to distributable cash**.
 - ▶ Ongoing shift to a value-based care model has accelerated provider consolidation, with large hospital / health systems acquiring physician-owned clinics to offer ‘full-spectrum’ of care; landlords benefit from **credit enhancement**.



Cardiology




Dialysis



Surgery Centers (ASC's)





Imaging Centers



Cancer Treatment



Multi-specialty clinic



¹Pantheon opinion. ²Source: Public information (as of Q1'2023). Reflects avg. MOB property size for the top-5 REIT owners.

³Source: GreenStreet; proprietary information – includes single-property transactions from 2019-2022 involving only single-tenant properties smaller than 25,000 sq. ft.; ⁴Source: DOC public information / Physicians Advocacy Institute.


2. Small-Format MOB (continued)

Spotlight: Dialysis

Dialysis real estate, a subtype of single-tenant / small-format MOB, benefits from a unique set of favorable demand trends, strong tenant credit and highly fragmented ownership¹

- ▶ Dialysis care is typically provided by specialty clinics located in standalone (usually off-campus) properties which are conveniently accessible for the local patient base.
- ▶ **Dialysis is a \$26bn annual revenue business** in the U.S., with ~80% of funding coming from Medicare.²
- ▶ Dialysis market is highly concentrated with the two largest providers (Fresenius, DaVita) accounting for ~75% market share.²
 - ▶ Fresenius and DaVita are publicly-listed companies, with investment grade (Fresenius) and BB credit ratings (DaVita).
- ▶ Chronic Kidney Disease ('CKD') is highly correlated with rates of obesity, heart disease and diabetes, conditions which are more prevalent in poorer / rural regions of the U.S. (specifically in the South & Midwest).³
 - ▶ The National Institute of Health projects nearly half of U.S. adults will be obese by 2030, including nearly 1 in 4 who will have severe obesity.
- ▶ Given higher rates of CKD in rural areas, dialysis clinics are commonly located outside of major population centers / primary markets, yet **serve as critical points of care** for patients living in a radius as wide as 30-45 miles.
- ▶ Strong continued demand growth is expected given the acceleration of population aging and medical advancements extending the life expectancy of older Americans.²
- ▶ As a result of strong historic demand for dialysis care and increased investor appetite for outpatient MOBs, the **dialysis sub-sector has experienced a secular decline in cap rates and risk premium** (defined as cap rate minus the 10 Year U.S. Treasury yield).⁴

Dialysis Cap Rate & Risk Premium (2011-2022)⁴



- ▶ Given the specialized nature of the sector, **operational expertise provides a competitive advantage in sourcing and underwriting investment opportunities in the dialysis sector.**¹
 - ▶ Relationships with the top dialysis companies (Fresenius, DaVita) and physician networks provide unique sourcing opportunities and insight during due diligence; ability to identify clinics with dominant local market positioning and high probability of long-term tenancy.
 - ▶ Industry relationships / reputation in market can promote 'first-call' status from sellers / brokers and access to off-market opportunities; trust in ability to conduct efficient diligence on 'short-fuse' opportunities.


¹Pantheon opinion. ²Source: 2022 United States Renal Data System Annual Data Report. ³Source: National Institute of Health.

⁴Source: Proprietary information; FRED. There is no guarantee that these trends will continue.

3. Trends Driving MOB Tenant Demand


The acceleration of U.S. population aging will continue to drive strong demand for healthcare

- ▶ The U.S. 65+ population, which as of 2021 accounted for 35% of healthcare expenditure while representing only 17% of the population, is projected to grow by ~17m by 2030 to 20% of the population.¹
- ▶ The aging population driving an acceleration in healthcare expenditures, which is projected to grow 5%+ per year to \$6.8tn by 2030 (+\$2.8tn / +58% vs. 2021).¹
 - ▶ 65+ population growth expected to drive outsized demand growth for certain outpatient specialties including orthopedics, cardiology / pulmonology and physical therapy.
- ▶ Impact of environmental pollution and global warming is also contributing to the growing need for healthcare services (estimated at \$800m+ per year), suggesting worsening global warming could act as additional accelerant to healthcare spending.²



The healthcare delivery model continues to shift toward outpatient care, with annual outpatient visits expected to increase by 20% by 2030.³

- ▶ Procedures and care which previously were done in hospitals (i.e., cardiology exams, orthopedic surgeries, lab work, physical therapy) are increasingly being shifted to outpatient settings, primarily driven by system-wide cost savings and patient convenience.
 - ▶ For example, it is estimated that orthopedic surgeries performed in outpatient settings are 30-40% less expensive vs. surgeries performed in hospitals (inpatient).⁴
- ▶ Outpatient visits overtook annual inpatient visits in the mid-2010s' and outpatient growth expected to accelerate with annual visits increasing by 20% by 2030, while inpatient visits are projected to fall by 1%.




¹Source: U.S. Census Bureau.
²Source: The Commonwealth Fund.
³Source: Kaiser Foundation.
⁴Source: BlueCross BlueShield.

4. MOB Operating Fundamentals


The MOB sector has demonstrated resilient performance through economic downturns, evidencing the essential (non-discretionary) nature of healthcare demand.^{1,2}

- ▶ MOB was the only major REIT sector to maintain positive NOI growth throughout both the Global Financial Crisis ('GFC') and COVID.
- ▶ MOB REIT occupancy declined by only 2.0% and 0.1% during the GFC and COVID, respectively, vs. a 4.0% and 4.0% decline in the traditional office sector.



Since the COVID pandemic, the MOB sector has demonstrated robust fundamentals, with occupancy and rent growth hitting decade-highs in the first half of 2023.³

- ▶ After falling only 0.1% during the pandemic, MOB sector occupancy began a steady upward trend in 2021, hitting a 10-year high of 92.7% in Q1 2023.
- ▶ Following the upward trend in occupancy, rent growth began accelerating in early 2022 rising to 3.9% in 2023, well above the trailing three-year average of 1.8%; acceleration in rent growth attributable to:
 - ▶ Strength in underlying demand, limited supply
 - ▶ Compensation for higher inflation environment; landlords have been able to negotiate for higher contractual lease escalations ranging from 2.5-3.0% (vs. 1.5-2.5% historically)



¹Source: GreenStreet,


²Pantheon Opinion.

³Source: Revista, JLL – as of Q1'2023. There is no guarantee that these trends will continue.

5. MOB Sector Supply


MOB has experienced only moderate inventory growth and is poised to positively absorb 2023 projected deliveries despite being elevated vs. prior years due to COVID slowdown

- ▶ MOB differs from other sectors in that there is limited speculative development; majority of MOB developments are build-to-suits, either by health systems for their own use or by developers for pre-identified tenant(s).
 - ▶ State imposed Certificate of Need ('CON') requirements regulate growth of various medical specialty practices, serving as a unique barrier to supply of new MOB's.
- ▶ Moderate inventory growth coupled with limited speculative development has resulted in steady sector occupancy, which has stayed above 90% for the last 20 years.¹
- ▶ Driven by the ongoing shift from inpatient to outpatient care, MOB developments have increasingly skewed toward off-campus locations; off-campus projects accounted for 75% of all MOB's delivered in 2022.¹



Surging construction costs for MOB development (up 26% in 2022) creates barrier to new supply and can make it difficult for new buildings to attract tenants given higher rent required for developers to make an appropriate return on investment.

- ▶ MOB inventory growth expected to slow meaningfully following deliveries of COVID backlog due to elevated construction costs and tighter lending conditions for construction loans.¹
- ▶ Based on strong market fundamentals and an expected slowdown in supply, MOB demand is expected to keep pace with supply supporting continued strength in occupancy and rent growth.²



¹Source: Revista, JLL – as of Q1'2023.


²Pantheon opinion.

6. MOB Investor Demand

Attracted by strong supply/demand trends and resilient performance, the MOB sector has experienced an ‘institutionalization’ over the past decade, with an expansion of dedicated operators and an influx of institutional capital.

- ▶ Fundraising by closed-end funds targeting healthcare sectors expanded at 25% CAGR since 2009.¹
- ▶ Record fundraising in 2020-21 (\$14bn raised) suggests there is a record level of dry powder targeting medical office and other healthcare property types; depth of capital demand is expected to drive continued growth in institutional investment volume and downward pressure on cap rates.^{1,2}


Dedicated Healthcare Capital Raising (2009-2021)¹



MOB investment volume has grown 15% per year over the past 10 years.³

- ▶ Since 2012, institutional investors investment volume has increased by 14% per year on average, with institutional share of total investment volume increasing from an average of 13% in the first half of the decade to ~20% in the latter half.³

MOB Transaction Volume & Institutional Share³



¹Source: Real Capital Analytics; JLL.


²Pantheon opinion.

³Source: Real Capital Analytics; Transwestern.



6. MOB Investor Demand (continued)

Supported by entrenched secular trends, medical office’s strong fundamentals and defensive characteristics have contributed to a steady decline in cap rates over the past decade.^{1,2}

- ▶ While MOB cap rates are partially correlated with interest rates, **the risk premium has declined by 120bps over the last 5 years**, suggesting that the sector has been ‘re-rated’ by institutions who are increasing capital inflows.
- ▶ Despite the recent rise in interest rates, the average trailing five-year (2018-23) MOB cap rate is ~50bps below the previous five-year period (2012-17).



- ▶ Valuations for MOB differs from other property types in that market size / location does not have a significant impact on cap rates, **while tenancy profile and lease term (WALT) have a more pronounced influence.**³



¹Source: GreenStreet; FRED.


²Pantheon Opinion.

³Source: Proprietary information – includes single-property transactions involving small-format MOB from 2019-2022. Market type determination based on Pantheon assessment.

6. MOB Investor Demand (continued)

The market has also seen diversified net lease ('NNN') REITs, which have experienced strong capital inflows, increasing their exposure to healthcare amidst a changing retail landscape, as evidenced through recent single-tenant healthcare portfolio acquisitions.

- ▶ Single-tenant NNN-leased MOB share many of the same characteristics as traditional property types owned by net lease REITs (grocery stores, pharmacies, home improvement store), including long-term NNN leases, strong tenant credit and minimal landlord capex resulting in predictable income yield.
- ▶ Given favorable MOB fundamentals, resilient demand and overlap in investment criteria, net lease REITs have become increasingly active participants in transactions involving portfolios of specialty healthcare portfolios.
- ▶ Realty Income, the largest NNN REIT by market cap, in Q1 2023 announced its acquisition of a 224-property portfolio of dental practices, and emphasized intentions to push further into consumer-centric healthcare.



¹Source: GreenStreet – as of June 2023. Includes three REITs (NNN, O, SRC) covered by GreenStreet with market capitalization data available going back to 2014.

Disclosure 1 – case studies

These case studies are examples of specific private transactions made by Pantheon funds / clients and are designed to assist prospective investors / clients to understand Pantheon's investment management style / strategy. It should NOT be regarded as a recommendation. Pantheon makes no representation or forecast about the performance, profitability or success of such transaction. Information concerning the performance of portfolio investments is available upon request, subject to confidentiality requirements. You should not assume that future recommendations will be profitable or will equal the performance of past recommendations. The statements above reflect the views and opinions of Pantheon as of the date of the investment analysis.

A list of all investments is available upon request.

IMPORTANT DISCLOSURE

This document and the information contained herein has been prepared by Pantheon and is the proprietary information of Pantheon; it may not be reproduced, provided or disclosed to others, without the prior written permission of Pantheon. For this purpose, "Pantheon" means the Pantheon operating entity that prepared and/or is distributing this document to the recipient. Pantheon operating entities are: Pantheon Ventures Inc. and Pantheon Ventures (US) LP which are registered as investment advisers with the U.S. Securities and Exchange Commission ("SEC"), Pantheon Securities LLC, which is registered as a limited purpose broker-dealer with the SEC and is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC"), Pantheon Ventures (UK) LLP which is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom, Pantheon Ventures (Ireland) DAC which is regulated by the Central Bank of Ireland ("CBI") and is an appointed representative of Pantheon Ventures (UK) LLP in respect of activities carried on in the United Kingdom, Pantheon Ventures (HK) LLP which is regulated by the Securities and Futures Commission ("SFC") in Hong Kong a corporation licensed by the SFC to conduct Type 1 (dealing in securities) and Type 4 (advising in securities) regulated activities and Pantheon Ventures (Asia) Limited, registered as a Type II Financial Instruments Business and Investment Advisory and Agency Business Operator under the registration entry "Director General of the Kanto Local Finance Bureau (Financial Instruments Business Operator) No. 3138" under the Financial Instruments and Exchange Act of Japan (the "FIEA") and a regular member of the Type II Financial Instruments Firms Association of Japan and Japan Investment Advisers Association. The registrations and memberships referred to above in no way imply any level of skill or training or that the SEC, FINRA, SIPC, FCA, CBI, SFC, the Type II Financial Instruments Firms Association of Japan or the Japan Investment Advisers Association have endorsed any of the referenced entities, their products or services, or the material in this document.

In the EEA, this document is distributed by Pantheon Ventures (Ireland) DAC to persons who are professional clients within the meaning of the EU Markets in Financial Instruments Directive (Directive 2014/65/EU) ("MIFID"). Any investment product to which this document relates may not be advised on, offered or sold in EEA member states to retail investors within the meaning of Regulation (EU) No 1286/2014 of 26 November 2014 on key information documents for packaged retail and insurance-based investment products ("PRIIPS Regulation") and no key information document (within the meaning of the PRIIPS regulation) will be produced in relation to any such investment product.

In Hong Kong, this document is distributed by a licensed representative of Pantheon Ventures (HK) LLP to persons who are Professional Investors as defined in Schedule 1 to the Securities and Futures Ordinance of Hong Kong.

In Japan this document is provided by Pantheon Ventures (Asia) Limited, to "Professional Investors" (tokutei toshika) as defined in Article 2, paragraph 31 of the FIEA.

In the U.S. and Canada, this document is prepared by Pantheon and is distributed by Pantheon Securities LLC, with respect to funds managed or advised by Pantheon or its affiliates. Furthermore, this material is an institutional communication intended solely for institutional investors, as defined by FINRA. Materials related to potential managed accounts that carry out similar strategies to those discussed herein are distributed by Pantheon Ventures (US) LP in the U.S. and Canada. The distribution of this document in Canada is restricted to recipients that are qualified "permitted clients" for purposes of NI 31-103 and "accredited investors" for purposes of NI 45-106.

In the United Kingdom, this document is distributed by Pantheon Ventures (UK) LLP to persons who are both (i) professional clients within the meaning of MIFID and within the meaning of Article 2(1)(8) of Regulation (EU) No. 600/2014, as retained in UK law and amended ("UK Professional Clients") and (ii) persons who are professional investors as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or who are persons falling within any of the categories of persons described in Article 49(2)(a) to (d) of that Order, or (iii) persons to whom this document may otherwise lawfully be communicated. Any investment product to which this document relates is not intended for retail investors (within the meaning of Article 4 of the PRIIPS Regulation, as retained in UK law and amended ("UK PRIIPS Regulation") and will be offered in the UK only to persons who are UK Professional Clients. No key information document (within the meaning of the UK PRIIPS Regulation) will be produced in relation to any such investment product.

In Australia, this document is distributed by Pantheon Ventures (UK) LLP only to persons who are wholesale clients under section 761G of the Corporations Act 2001 (Cth) ("Wholesale Clients"). By receiving this document in Australia, you represent and warrant that you are a Wholesale Client. Pantheon Ventures (UK) LLP is exempt from the requirement to hold an Australian financial services licence under the Corporations Act 2001 (Cth) in relation to any financial services provided in Australia to Wholesale Clients under ASIC Class Order 03/1099. Pantheon Ventures (UK) LLP is regulated by the FCA under the laws of England and Wales, which differ from Australian laws. Pantheon Ventures (UK) LLP relies on the Australian Corporations (Repeal and Transitional Instrument) 2016/396 which grants transitional continuance relief to foreign financial services providers relying on Australian Class Order 03/1099 in order to provide financial services to Wholesale Clients in Australia.

In other countries, this document is distributed by Pantheon, or on Pantheon's behalf by a third-party distributing agent, only to persons which are institutional investors to whom this document can be lawfully distributed without any prior regulatory approval or action. This document is provided to the intended party only and may not be shared, in whole or in part, or distributed without the express written consent of Pantheon.

By accepting this document, you acknowledge and agree that this material is provided for your use only and that you will not distribute or otherwise make this material available to any other person without the prior written permission of Pantheon.

Important information regarding: Opening a new "Account"

To help the government fight the funding of terrorism and money laundering activities, federal law requires all financial institutions to obtain, verify, and record information that identifies each customer who opens an account. What this means for you: When you open an account, Pantheon may ask for documents or information related to your principal place of business, local office or other physical location; taxpayer identification number; and other documents demonstrating your lawful existence such as certified articles of incorporation, a government-issued business license, a partnership agreement, or a trust instrument, and other identifying documents.

IMPORTANT DISCLOSURE

This document is a marketing communication and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Nothing in this document constitutes an offer or solicitation to invest in a fund managed or advised by Pantheon or any of its affiliates or recommendation to purchase any security or service. This material is qualified in its entirety by the information contained in any investment product's offering documents or the governing documents of a separately managed account, including any prospectus or other offering memorandum related thereto (collectively, a "Prospectus") and any governing document of such product or account. Furthermore, this material is an institutional communication intended for institutional recipients. Any offer or solicitation of an investment in an investment product may be made only by delivery of the investment product's Prospectus to qualified investors. Prospective investors should rely solely on the Prospectus and governing documents of any investment product in making any investment decision. The Prospectus contains important information, including, among other information, a description of an investment product's risks, objectives, investment program, fees and expenses, and should be read carefully before any investment decision is made. An investment in an investment product is not suitable for all investors. The information contained in this document has been provided as a general market commentary only and does not constitute any form of legal, tax, securities or investment advice. It does not take into account the objectives, financial situation, risk tolerance, attitude to risk and investment restrictions of any persons, which are necessary considerations before making any investment decision. Unless stated otherwise all views expressed herein represent Pantheon's opinion. The general opinions and information contained in this document should not be acted or relied upon by any person without obtaining specific and relevant legal, tax, securities or investment advice. Certain information included in this document is derived from third-party sources that are believed by Pantheon to be reliable, but Pantheon does not guarantee their accuracy or completeness. The information contained in this document is current as of the dates indicated, however Pantheon does not undertake to update this document, and the information and views discussed may change without notice. Legal, accounting and tax restrictions, transaction costs and changes to any assumptions may significantly affect the economics and results of any transaction or investment. In general, alternative investments such as private equity, infrastructure and real assets, or private debt/credit involve a high degree of risk, including potential loss of principal invested. These investments can be highly illiquid, charge higher fees than other investments, and typically do not grow at an even rate of return and may decline in value. These investments are not subject to the same regulatory requirements as registered investment products. **In addition, past performance is not indicative of future results. Future performance is not guaranteed and a loss of principal may occur. Market and exchange rate movements may cause the capital value of investments, and the income from them, to go down as well as up and an investor may not get back the amount originally invested. This document may include "forward-looking statements" that can be identified by the use of forward-looking terminology such as "may," "will," "should," "expect," "anticipate," "estimate," "intend," "continue," or "believe" or the negatives thereof or other variations thereon or comparable terminology. All projections, forecasts or related statements or expressions of opinion are forward-looking statements. Although Pantheon believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct, and such forward-looking statements should not be regarded as a guarantee, prediction or definitive statement of fact or probability.**

Portfolio, volatility or return targets or objectives, if any, are used solely for illustration, measurement or comparison purposes and as an aid or guideline for prospective investors to evaluate a particular investment product's strategies, volatility and accompanying information. Such targets or objectives reflect subjective determinations of an Investment Manager based on a variety of factors including, among others, the investment product's investment strategy and prior performance (if any), volatility measures, portfolio characteristics and risk, and market conditions. Volatility and performance will fluctuate, including over short periods, and should be evaluated over the time period indicated and not over shorter periods. Performance targets or objectives should not be relied upon as an indication of actual or projected future performance. Actual volatility and returns will depend on a variety of factors including overall market conditions and the ability of an Investment Manager to implement an investment product's investment process, investment objectives and risk management.

Potential investment program risks

- ▶ Pantheon's investment strategies relate to investments in private funds investing in alternative investments such as private equity, infrastructure and real assets, or private debt/credit, or direct real estate, or other direct investments in such alternative investments. In general, such alternative investments involve a high degree of risk, including potential loss of principal invested. These investments can be highly illiquid, charge higher fees than other investments, and typically do not grow at an even rate of return and may decline in value. These investments are not subject to the same regulatory requirements as registered investment products. An investment in a fund investing in alternative investments involves a high degree of risk. Such investments are speculative, subject to high return volatility and will be illiquid on a long-term basis. Investors may lose their entire investment.
- ▶ Managers of funds investing in alternative assets typically take several years to invest a fund's capital. Investors will not realize the full potential benefits of the investment in the near term, and there will likely be little or no near-term cash flow distributed by the fund during the commitment period. Interests may not be transferred, assigned or otherwise disposed of without the prior written consent of the manager or general partner.
- ▶ Funds investing in alternative assets are subject to significant fees and expenses, typically, management fees and a 20% carried interest in the net profits generated by the fund and paid to the general partner, manager or an affiliate thereof. Investments in such funds are affected by complex tax considerations.

IMPORTANT DISCLOSURE

- ▶ Funds investing in alternative assets may make a limited number of investments. These investments involve a high degree of risk. In addition, funds may make minority investments where the fund may not be able to protect its investment or control, or influence effectively the business or affairs of the underlying investment. The performance of a fund may be substantially adversely affected by a single investment. Private fund investments are less transparent than public investments and private fund investors are afforded fewer regulatory protections than investors in registered funds or registered public securities.
- ▶ Investors in funds investing in alternative assets are typically subject to periodic capital calls. Failure to make required capital contributions when due will cause severe consequences to the investor, including possible forfeiture of all investments in the fund made to date. A material number of investors failing to meet capital calls could also result in the fund failing to meet a capital call applicable to participating in an investment. Such a default by the fund could lead to the permanent loss of all or some of the applicable fund's investment, which would have a material adverse effect on the investment returns for non-defaulting investors participating in such investment.
- ▶ Governing investment documents or the related Prospectus or the managed account agreement, as the case may be, are not reviewed or approved by federal or state regulators and privately placed interests are not federally or state registered.
- ▶ Fees and expenses – which may be substantial regardless of any positive return – will offset an investment product's profits. If an investment product's investments are not successful, these fees and expenses may, over a period of time, deplete the net asset value of the investment product.
- ▶ Pantheon and its affiliates may be subject to various potential and actual conflicts of interest.
- ▶ An investment product may employ investment strategies or techniques aimed to reduce the risk of loss which may not be successful.

The above summary is not a complete list of the risks, tax considerations and other important disclosures involved in investing in an investment product and is subject to the more complete disclosures in such investment product's Prospectus and/or managed account agreement, and/or governing documents of any investment product which must be reviewed carefully prior to making any investment in such investment product.

Pantheon has taken reasonable care to ensure that the information contained in this document is accurate at the date of publication. However, no warranty or guarantee (express or implied) is given by Pantheon as to the accuracy of the information in this document, and to the extent permitted by applicable law, Pantheon specifically disclaims any liability for errors, inaccuracies or omissions in this document and for any loss or damage resulting from its use.

Any reference to the title of "Partner" in these materials refers to such person's capacity as a partner of Pantheon Ventures (UK) LLP. In addition, any reference to the title of "Partner" for persons located in the United States refers to such person's capacity as a limited partner of Pantheon Ventures (US) LP.

Copyright © Pantheon 2023. All rights reserved.